Pfizer’s antibody-drug conjugate Padcev, paired with Keytruda, has shown a survival benefit for patients with invasive bladder cancer who cannot undergo cisplatin chemotherapy. In the EV-303 trial, the combination given before and after bladder removal not only prolonged the time before recurrence but also extended overall survival compared to surgery alone. This follows Pfizer’s $43 billion acquisition of Seagen, bringing Padcev into its oncology portfolio, and reflects the ongoing momentum in targeted and immuno-oncology approaches. The results could signal a strategic shift in treatment pathways for a hard-to-treat patient segment.

Read the full story to explore the trial’s implications and market potential.